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Abstract
Background: CD44 is a major cellular receptor for hyaluronic acids. The stem structure of CD44 encoded by ten normal
exons can be enlarged by ten variant exons (v1-v10) by alternative splicing. We have succeeded in preparing MV5 fully
human IgM and its class-switched GV5 IgG monoclonal antibody (mAb) recognizing the extracellular domain of a CD44R1
isoform that contains the inserted region coded by variant (v8, v9 and v10) exons and is expressed on the surface of various
human epithelial cancer cells.
Methods and Principal Findings: We demonstrated the growth inhibition of human cancer xenografts by a GV5 IgG mAb
reshaped from an MV5 IgM. The epitope recognized by MV5 and GV5 was identified to a v8-coding region by the analysis of
mAb binding to various recombinant CD44 proteins by enzyme-linked immunosorbent assay. GV5 showed preferential
reactivity against various malignant human cells versus normal human cells assessed by flow cytometry and
immunohistological analysis. When ME180 human uterine cervix carcinoma cells were subcutaneously inoculated to
athymic mice with GV5, significant inhibition of tumor formation was observed. Furthermore, intraperitoneal injections of
GV5markedly inhibited the growth of visible established tumors from HSC-3 human larynx carcinoma cells that had been
subcutaneously transplanted one week before the first treatment with GV5. From in vitro experiments, antibody-dependent
cellular cytotoxicity and internalization of CD44R1 seemed to be possible mechanisms for in vivo anti-tumor activity by GV5.
Conclusions: CD44R1 is an excellent molecular target for mAb therapy of cancer, possibly superior to molecules targeted by
existing therapeutic mAb, such as Trastuzumab and Cetuximab recognizing human epidermal growth factor receptor
family.
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Introduction
CD44 is a type I cell-surface glycoprotein, which functions as
the major cellular adhesion molecule for hyaluronic acids [1–3].
Standard CD44 (CD44s) encoded by the ten normal exons (ex1-
5 and ex16-20) can be enlarged by the inserts encoded by various
combinations of variant exons (ex6-15 or v1-v10) of CD44 by
alternative splicing [3,4]. Although the physiological significance
of the alternative splicing of CD44 remains unclear, some
variant CD44 (CD44v) molecules were reported to be over-
expressed in various malignancies of rodent and human systems
[5–8].
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encoded by v8 (ex13), v9 (ex14) and v10 (ex15) exons is selectively
expressed in various human epithelial cancers. For example,
CD44R1 mRNA is elevated in human colon, bladder, lung, larynx
and breast cancers [8], and immunohistological analysis (IHA) also
revealed that CD44R1 protein was over-expressed in lung pleural
samples compared with that in adjacent normal tissues, using
rabbit polyclonal antibodies raised against recombinant CD44
protein [8]. Furthermore, we have recently demonstrated that
mouse homolog of human CD44R1 is expressed in precancerous
regions, possibly containing cancer stem cells (CSCs) or tumor-
initiating cells, during mouse gastric carcinogenesis [9,10].
However, since specific fully human monoclonal antibodies
(mAb) recognizing the extracellular domain of human CD44R1
expressed on living tumor cells have not been available until now,
precise evaluation of the therapeutic effect of anti-CD44R1 mAb
on human malignancies remains to be undertaken. In this study,
we report the growth inhibition of human cancer xenografts in
athymic mice by locally or systemically administered fully human
mAb recognizing CD44R1, and discuss the specificity, anti-tumor
mechanisms and usefulness of fully human anti-CD44R1 mAb in
cancer therapy.
Results and Discussion
CD44, which binds hyaluronates, is a credible marker molecule
for CSCs [11–16], and is significantly involved in the metastasis of
tumor cells [16–19]. Thus, CD44 is considered to be a promising
molecular target for cancer therapy using mAb. Since CD44s is
expressed in various normal tissues [20], we have focused on
tumor-selective splice-variant CD44v proteins. Among over 1000
theoretically possible splice-variant CD44v proteins [21], CD44R1
having the insert coded by v8, v9 and v10 exons is selectively
expressed on various epithelial cancer cells [8].
We have recently prepared five anti-human CD44 fully human
IgM mAb (MV1 against CD44s, and MV2, MV3, MV4 and MV5
against CD44R1) from cell fusions between mouse myeloma cells
and spleen cells of Kirin-Medarex (KM) mice [22] immunized
against recombinant human CD44 proteins produced in Escherichia
coli. In this paper, we present the preparation of class-switched
anti-CD44R1 human IgG mAb (GV5), specificity of MV1, MV5
and GV5, and in vivo and in vitro anti-tumor effect of GV5.
Fully human IgM and IgG mAb against human CD44
proteins were produced
Five anti-human CD44 fully human IgM mAb (MV1, MV2,
MV3, MV4 and MV5) were produced against a recombinant
CD44 (R1a; Dex5-v8-v9-v10-Dex16) protein produced in Esche-
richia coli [8]. MV1 reacted with RH7777 rat hepatoma cells
expressing CD44s or CD44R1, and MV2, MV3, MV4 and MV5
reacted specifically with RH7777 cells expressing CD44R1 (data
not shown). To evaluate the reactivity of human mAb with in vivo
tumors, we performed IHA (Fig. 1). MV1 and MV5 definitely
stained cell membranes of in vivo tumor from ME180 human
uterine cervix cancer developed in athymic mice, and CD44R1
was heterogeneously expressed in human cancer xenografts,
although MV2, MV3 and MV4 showed relatively weak reactions
compared with MV5 (Fig. 1). Therefore, we have reshaped (class-
switched) MV5 human IgM to GV5 human IgG. Reactivity of
GV5 with in vivo tumors from ME180 was also positive at the cell
membrane of these tumor cells (Fig. 2), and CD44R1 was
heterogeneously expressed in the tumor as in the case with the
staining of the ME180 tumor by MV5. In contrast, the expression
of HER2 recognized with Trastuzumab was relatively uniform in
the ME180 tumor, and the expression of CD20 recognized by
Rituximab was completely negative.
Specificity and epitope of fully human MV1 and MV5 IgM,
and class-switched GV5 IgG mAb against CD44 were
determined
Specificities of MV1, MV5 and GV5 were compared for the
reactivity with HEK293F human embryonic kidney cells express-
ing CD44R1 or CD44s (Fig. 3A), as described elsewhere [10,23].
MV5 and GV5 reacted specifically with CD44R1-green fluores-
cent protein (GFP)-expressing cells in a GFP-expression-dependent
manner; however, these mAb did not react with cells expressing
CD44s-GFP, demonstrating that GV5 maintains the specificity of
Figure 1. Immunoperoxidase staining of human xenografts developed in athymic mice with anti-CD44 fully human IgM mAb. Tissue
sections of human ME180 tumors developed in athymic mice were fixed with PFA, and were sequentially incubated with human mAb, species-
specific biotinylated anti-human IgG + IgM (H+L), ABC reagent and substrate solution containing DAB and H2O2. Nuclei were stained with
hematoxylin.
doi:10.1371/journal.pone.0029728.g001
Fully Human Monoclonal Antibody to Human CD44v
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29728MV5 and specifically recognizes a human CD44R1 protein by
flow cytometry (FCM). In contrast, MV1 reacted with HEK293F
cells expressing CD44s-GFP or CD44R1-GFP. The specificity of
human mAb was also substantiated by FCM analysis using
RH7777 rat cells transfected with cDNA of human CD44s or
CD44R1 (data not shown). Next, MV1, MV5 and GV5 were
assessed for reactivity with various recombinant human CD44
proteins fused to glutathione S-transferase (GST) (Fig. 3B). R1a is
an immunogen for the production of anti-CD44 human mAb, and
R1b contains shorter polypeptides in ex5 and v8 regions than R1a.
The epitope defined with fully human mAb was localized to an
ex5-coding region for MV1, and a v8-coding region for MV5 and
GV5 by enzyme-linked immunosorbent assay (ELISA). The
peptide epitope defined with MV5 or GV5 seemed to be exposed
in human cells because these mAb definitely and specifically
reacted with HEK293F cells expressing CD44R1, although
CD44R1 is heavily glycosylated and the expression of these
epitopes could be affected by the glycosylation varying between
cell types or cell conditions.
Anti-CD44R1 fully human GV5 selectively reacted with
human carcinoma cell lines, but not with various human
normal cells
Some of the existing therapeutic mAb are targeted to the
human epidermal growth receptor (HER) family [24–27]. We
compared the reactivity of GV5, Cetuximab (anti-HER1) and
Trastuzumab (anti-HER2) with HCT116 human colon cancer
cells, normal human epidermal keratinocytes (NHEK) and human
umbilical vein endothelial cells (HUVEC) (Fig. 4A, C). GV5,
Cetuximab and Trastuzumab were definitely reactive with
HCT116 human cancer cells. GV5 weakly reacted with NHEK,
although Cetuximab strongly and Trastuzumab moderately
reacted with NHEK. Furthermore, GV5 was almost unreactive
with HUVEC, although Cetuximab and Trastuzumab substan-
tially reacted with HUVEC. Next, we examined the reactivity of
GV5 against various additional human cell lines (Fig. 4B). GV5
definitely reacted with various cultured human epithelial cancers
(BT20 breast, KATOIII stomach, LS-174T colon, ME180 cervix,
KPK-1 kidney and KU-1 bladder), although this mAb did not
react or only weakly reacted with Molt-4 T leukemia, SK-MEL-37
melanoma and non-cancerous cell lines from adult skin (EK325),
fetal intestine (Int407) and embryonic kidney (HEK293F). GV5
also reacted with MKN-7 stomach and HeLa-S uterine cervix
carcinoma cell lines, but not with U-2OS osteosarcoma, Jurkat,
Daudi and HL60 leukemia cell lines (Fig. 4C). Expression of
CD44R1 in many carcinoma cells was heterogeneous (Fig. 4B), as
in the cases of human xenografts in athymic mice (Fig. 1, Fig. 2).
In addition, GV5 did not react with resting small lymphocytes at
all; it is also of interest that it did not react with lymphocytes
stimulated with recombinant human interleukin-2 (IL-2) for 48 h
or 12-O-tetradecanoylphorbol-13-acetate (TPA) plus Ca iono-
phore (A23187) for 24 h, indicating that activated T and B
lymphocytes are not reactive with GV5 (Fig. 4C). The specificity
of GV5 indicates that CD44R1 is a tumor-selective and superior
target molecule compared with HER1 or HER2. In fact, serious
skin toxicity was observed in the treatment of Cetuximab against
colon cancer patients, probably because of binding to HER1 on
skin keratinocytes. In the context of the expression of HER2, GV5
strongly reacted with a BT20 triple-negative breast cancer cell line
that does not express estrogen and progesterone receptors and
HER2, although this mAb did not react with HER2-over-
expressing SK-BR-3 breast cancer cell line (Fig. 4B, C).
Therefore, we expect that anti-CD44R1 therapeutic mAb could
compensate for anti-HER2 mAb in the therapy of breast cancers.
CD44R1 was specifically detected in human epithelial
cancer tissues
First, the distribution of CD44s and CD44R1 in human cancers
was analyzed with rat mAb (RV7 and RV9) against human CD44,
since immunostaining of human tissues with GV5 followed by
anti-human immunoglobulins did not result in the obvious result
(data not shown). In IHA on human breast and colon tissues
(Fig. 5), both RV7-defined CD44s and RV9-defined CD44R1
(v8) were definitely expressed in the cell membrane of breast and
colon cancer cells, although CD44s but not CD44R1 was also
expressed on cells in the stroma. Expression of CD44R1 in normal
breast epithelial cells was low and was negative in colon epithelial
cells. In addition, CD44R1 was heterogeneously expressed in
cancer cells, as in the case with the staining of human cancer
xenografts (Fig. 1 and Fig. 2) and cancer cell lines (Fig. 4B)b y
GV5 anti-CD44R1 human mAb. In IHA on human tonsils, RV9
anti-CD44R1 (v8) mAb weakly stained the epithelium, especially
cells in the basal layer, but did not stain lymphoblastoid cells in the
germinal center of the tonsil tissue, although RV7 anti-CD44s
mAb definitely stained cells in this region, in addition to cells in the
whole epithelium (data not shown). These findings coincide well
with the unreactivity of GV5 with activated human lymphocytes
(Fig. 4C). These results from FCM and IHA have demonstrated
excellent cancer-specificity of CD44R1, undoubtedly superior to
that of CD44s. We next examined the reactivity of biotinylated
GV5 with human tissue specimens. GV5 definitely reacted with
squamous carcinomas of uterine cervix (primary cancer), skin
(primary cancer) and lung (metastatic cancer to soft tissues),
adenocarcinomas of stomach and colon, but not with aggregated
lymphatic nodules of vermiform appendix (Fig. 6). Thus, the
expression of CD44R1 is limited to epithelial cancers, and is not
elevated in the process of lymphocyte activation in vitro or in vivo,
although the expression of a given intrinsic oncoprotein in
Figure 2. Immunoperoxidase staining of human xenografts
developed in athymic mice with an anti-CD44R1 fully human
IgG mAb (GV5). Tissue sections of human ME180 tumors developed
in athymic mice were fixed with cold acetone, and were sequentially
incubated with primary mAb, species-specific biotinylated anti-human
IgG Fcc, ABC reagent and substrate solution containing DAB and H2O2.
Nuclei were stained with hematoxylin. Upper or lower panels
respectively show low or high magnification of the stained tissues.
doi:10.1371/journal.pone.0029728.g002
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[28,29].
Anti-CD44R1 GV5 human mAb exhibited in vivo
therapeutic effect on human carcinomas in xenograft
models
GV5 was evaluated for anti-tumor effect against human tumors
in athymic mice. The size of each tumor formed was periodically
measured, as described elsewhere [30–32]. First, GV5 was
examined for the effect on tumor formation by ME180 human
cervix cancer cells in a tumor neutralization model [33]. This
model to evaluate the local effect of antibodies against tumor
growth historically originated from Winn’s test [34] intended for
evaluation of the anti-tumor effect of cytotoxic T lymphocytes.
Cancer cells were inoculated subcutaneously to athymic mice
with or without GV5 (50 mg/site), and tumor growth in GV5
treatedmice was significantly inhibited compared with that of
control mice (Fig. 7). Next, GV5 was examined for anti-tumor
effect against an HSC-3 human larynx cancer in an established
tumor model [35]. In this systemic administration of mAb to
tumor-bearing mice, we deliberately adopted intraperitoneal but
not intravenous injection for the administration of an exact
amount of mAb to each mouse. Seven days after HSC-3 cells
were inoculated subcutaneously to athymic mice and a visible
tumor in each mouse was confirmed, GV5or vehicle control was
intraperitoneally injected twice at an interval of a week. In this
experimental model, tumor growth in GV5 treatedmice was
again significantly inhibited compared with that of control mice
(Fig. 8).
GV5 induced internalization of CD44R1 and ADCC in vitro
To analyze the mechanisms of the in vivo anti-tumor effect of
GV5 against human cancer xenografts in athymic mice,
internalizations of CD44R1, complement-dependent cytotoxicity
(CDC) and antibody-dependent cellular cytotoxicity (ADCC) by
GV5 were examined. Since the dysfunction of CD44R1 by mAb
Figure 3. Specificity and epitope of anti-CD44 fully human mAb. (A) MV1 (left), MV5 (middle) and GV5 (right) were compared for the
reactivity with HEK293F cells expressing human CD44R1-GFP (upper) or human CD44s-GFP (lower) by FCM. (B) Reactivity of antibodies against various
GST-fused recombinant CD44 proteins (R1a and R1b; Dex5-v8-v9-v10-Dex16, v8, v9, v10 and ex5) fused to GST was determined by ELISA. Difference in
the length of Dex5 and Dex16 between R1a and R1b recombinant proteins is described in ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0029728.g003
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Trastuzumab were compared for the reactivity with HUVEC, NHEK and HCT116 by FCM (histograms) with an Accuri C6 flow cytometer (A). Reactivity
of GV5 with various human cells was analyzed by FCM, and depicted as histograms (B) using a BD-LSR flow cytometer and as DMFI (C) using an Accuri
C6 flow cytometer.
doi:10.1371/journal.pone.0029728.g004
Figure 5. Immunoperoxidase staining of human breast and colon tissues with anti-human CD44 rat mAb. Reactivity of anti-human
CD44s or anti-human CD44R1 (v8) rat mAb with breast and colon tissue sections from human surgical specimens was analyzed with ABC
immunoperoxidase staining. Sections from PFA-fixed and paraffin-embedded human breast and colon tissues were treated with microwaves in
citrate buffer for the retrieval of antigens, and incubated with RV7 or RV9 rat mAb. After being rinsed in PBS, tissue sections were sequentially
incubated with species-specific biotinylated donkey anti-rat IgG (H + L), ABC reagent and substrate solution containing DAB and H2O2. Nuclei were
stained with hematoxylin. Non-Cancer or Cancer tissues mean specimens from an identical patient.
doi:10.1371/journal.pone.0029728.g005
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through a lack of signal from an adhesion substrate, we examined
the effect of GV5 on the distribution of cell-surface CD44 proteins.
By the addition of GV5 to the culture of HSC-3 cells for 12 h,
approximately 50% of CD44R1 proteins disappeared from the cell
surface (Fig. 9A). CDC using GV5 combined with mouse, rabbit
or human serum did not result in the death of tumor cells
(Fig. 9B). In ADCC, splenocytes of athymic mice were pre-
cultured with IL-2 for 12 h to enhance the killing activity of
effector cells. By the use of IL-2-treated effector cells, GV5clearly
augmented the cytotoxicity against HSC-3 tumor cells in ADCC
(Fig. 9C, D).
GV5 induced efficient ADCC with human effector cells
Since we confirmed ADCC activity of GV5 with mouse effector
cells, we next examined ADCC activity of GV5 with human
effector cells. GV5 showed significant ADCC activity against
HSC-3 tumor cells with IL-2-stimulated human peripheral blood
lymphocytes (PBL) as effector cells, even at a low effector/target
(E/T) ratio of 2.5 (Fig. 10A). At an E/T ratio of 10, GV5 showed
Figure 6. Immunoperoxidase staining of human tissues with anti-human CD44 fully human IgG mAb (GV5). Sections from PFA-fixed
and paraffin-embedded human tissues were treated with microwaves in citrate buffer for the retrieval of antigens, and incubated with biotinylated
GV5. After being rinsed in PBS, tissue sections were incubated with ABC reagent and substrate solution containing DAB and H2O2. Nuclei were
stained with hematoxylin.
doi:10.1371/journal.pone.0029728.g006
Figure 7. Therapeutic effect of anti-CD44R1 fully human mAb in the tumor neutralization model. Tumor neutralization model was
adopted. ME180 human tumor cells (1.0610
6) with or without mAb (50 mg/site) in 200 ml of PBS were subcutaneously inoculated into the right dorsal
flank of each animal. The size of each tumor formed was periodically measured, and tumor volume (mm
3) was calculated by the formula
0.46(length)6(width)
2. Results were analyzed statistically by two-way ANOVA tests with repeated measures.
doi:10.1371/journal.pone.0029728.g007
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human effector cells alone, at all time points between 2 h and
7h( Fig. 10B).
In this study, we have successfully produced fully human GV5
mAb specifically recognizing CD44R1, and demonstrated the
growth inhibition of human cancer xenografts in athymic mice by
GV5. As to the anti-tumor mechanisms against human xenografts
by GV5 in athymic mice, we tentatively propose the contribution
of induced internalization of CD44R1 by GV5 and augmented
cytotoxicity in ADCC by mouse effector cells with GV5. We also
expect that GV5can display an ADCC-mediated therapeutic effect
on human malignancies, since GV5has showed ADCC activity
with human PBL as effector cells. Effects of anti-CD44R1 mAb on
the incorporation of hyaluronate are now under investigation;
however, we have already confirmed that GV5 could induce
internalization of CD44R1 from the cell surface, suggesting
possible effects on the incorporation of hyaluronate and augment-
ed anti-tumor effect of this mAb, in addition to ADCC activity.
Recently, specific chimeric or humanized mAb against the
extracellular domains of HER2 [24,25], HER1 [26,27] and CD20
[36–38] have been introduced for the treatment of breast cancer,
colorectal cancer or B cell malignancies, respectively. Although
phase I clinical trials with anti-CD44v6 chimeric mAb against
squamous cell carcinomas have recently been performed [39–41],
serious skin toxicity was observed probably because of binding to
CD44v6 on skin keratinocytes [39,40]. In this context, reactivity of
GV5 with human normal skin keratinocytes was negative or
negligible (Fig. 3A), suggesting low skin toxicity of our anti-
CD44R1 (v8) fully human mAb.
Accumulated evidence has shown that CD44 is characteristi-
cally expressed in CSCs of various tissue origins [11–16]. We now
focus our attention on CD44v (CD44R1) but not CD44s expressed
on the surface of CSCs in the precancerous region of gastric
adenocarcinomas of K19-Wnt1/C2mE transgenic mice [9,10].
Reactivity of GV5 with ME180 or HSC-3 seemed relatively
heterogeneous; however, tumor formation or tumor growth was
almost completely inhibited by GV5, suggesting that CSCs are
mainly composed of GV5-reactive CD44R1
high cells but not of
GV5-unreactive CD44R1
low cells. In this context, our recent data
have provided evidence that the expression of CD44R1 and its
association with xCT cysteine-glutamate antiporter, a light chain
subunit of CD98 oncoprotein [10,23,30–32,42,43], block the
reactive oxygen species (ROS)-induced stress signaling that results
in growth arrest, cell differentiation and senescence, and thereby
promote the proliferation of cancer cells and the formation of
lethal gastrointestinal tumors [44]. Given that CD44R1-expressing
CSCs play a central role in resistance to cancer therapy, it should
be postulated that therapeutic mAb could target the CD44R1
high
cell population in cancer.
Our present analyses strongly indicate that cancer therapy with
anti-CD44R1 fully human mAb is promising, especially against
various human epithelial cancers such as adenocarcinomas of
breast, stomach and colon, transitional cell carcinoma of bladder,
and renal carcinoma, in addition to squamous cell carcinomas
from various body regions.
Materials and Methods
Cells and cell-culture conditions
Cell lines from human larynx carcinoma (ca) (HSC-3), breast ca
(BT20, SK-Br-3), gastric ca (GAS-1, MKN-7, MKN-28, KA-
TOIII), colorectal ca (LS-174T, HCT116), uterine cervix ca
(ME180, HeLa-S), renal ca (KPK-1, TOS-1), bladder ca (KU-1),
melanoma (SK-Mel-37), osteosarcoma (U-2OS), fetal intestine
Figure 8. Therapeutic effect of anti-CD44R1 fully human mAb in the established tumor model. Established tumor model was adopted.
Seven days after human larynx carcinoma-derived HSC-3 tumor cells (1.0610
6) in 200 ml of PBS were inoculated subcutaneously to athymic mice and
visible tumor in each mouse was confirmed, 500 ml of PBS with or without GV5 (100 mg) was intraperitoneally inoculated at day 7 and day 14 (vertical
arrows). The size of each tumor formed was periodically measured, and tumor volume (mm
3) was calculated by the formula 0.46(length)6(width)
2.
Results were analyzed statistically by two-sided Student’s t tests (upper), and by two-way ANOVA tests with repeated measures (lower). Vertical bars
show standard deviations.
doi:10.1371/journal.pone.0029728.g008
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provided by Tanabe Mitsubishi Pharm.) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 7% heat-inactivated fetal
bovine serum (FBS; ICN Biomedicals, Aurora, OH, USA) in a
humidified incubator (5% CO2)a t3 7 uC. GAS-1, MKN-28 or
TOS-1 was respectively obtained from Kotanagi H (Akita
University), Japanese Collection of Research Bioresources (JCRB)
Cell Bank or Satoh M (Tohoku University). T-cell leukemias
(Jurkat, Molt-4), B-cell leukemia (Daudi), promyelocytic leukemia
(HL60) of human origin, human PBL with or without recombinant
human interleukin 2 (IL-2, 100 IU; Shionogi & Co. Ltd., Osaka,
Japan) and mouse splenocytes with IL-2 (100 IU) for ADCC,
mouse myelomas (SP2, X63) and established hybridoma cells were
cultured in RPMI 1640 medium (RPMI; Sigma-Aldrich) supple-
mented with 7% heat-inactivated FBS under the conditions
mentioned above. To obtain activated human lymphocytes for
FCM, PBL were also cultured and stimulated with IL-2 (100 IU)
for 48 h or 12-O-tetradecanoylphorbol-13-acetate (TPA, 20 ng/
ml; Sigma-Aldrich) plus Ca ionophore (A23187, 0.3 mM; Calbio-
chem, La Jolla, CA, USA) for 24 h in RPMI with 7% FBS.
HUVEC (Takara Bio Inc., Otsu, Japan) were maintained in
EGM-2 medium (Lonza, Walkersville, MO, USA) and used at
third to fifth passages. NHEK (Takara Bio Inc.) were cultured in
HuMedia-KG2 (Lonza) and used at third to fourth passages.
HEK293F human embryonic kidney cells (Invitrogen, Carlsbad,
CA, USA) and a human epidermal keratinocyte-derived cell line
(EK325) established by us were cultured in FreeStyle293
expression medium (Invitrogen) in a humidified incubator (5%
CO2). GFP was genetically fused to the cytoplasmic carboxyl
terminus of human CD44s or CD44R1 in a pAcGFP expression
vector (BD Biosciences, Mountain View, CA, USA), and
HEK293F and RH7777 cells were respectively transfected with
these CD44-GFP plasmids by 293fectin (Invitrogen) or Lipofecta-
mine 2000 (Invitrogen), in accordance with the manufacturer’s
instructions, selected using culture media containing G418
(Nacalai Tesque, Kyoto, Japan) diluted to 400 mg/ml, and
clone-sorted for cellular green fluorescence using a JSAN cell
Figure 9. Internalization of CD44R1, CDC and ADCC by GV5 fully human mAb. (A) HSC3 cells were cultured with or without GV5 (10 mg/ml)
for 12 h, and were immunostained with GV5 followed by FITC-conjugated donkey anti-human IgG (H+L). Cell-surface CD44R1 proteins in these cells
were detected by FCM. Experiments were repeated three times, and similar results were obtained. (B) After HSC-3 cells and sera for complement and
mAb were mixed and incubated in each well of U-bottomed 96-well plate for 1 h, DAPI was added to each well. Percentages of DAPI-stained cells
(dead cells) were calculated by FCM. Experiments were repeated three times, and similar results were obtained. (C) HSC-3 cells (1.5610
5) were mixed
with effector cells of splenocytes (3610
6 or 9610
6) from KNS nude mice, which were pre-cultured overnight with lL-2, with or without mAb, in each
well of U-bottomed 96-well plate for 5 h, and PI was added to each well. Cytotoxicity was analyzed using an Accuri flow cytometer. R1, HSC3 human
target cells; R2, mouse effector cells; R3, PI-stained dead cells in R1; R4, PI-unstained living cells in R1. (D) Cell death (%) of HSC-3 cells by mouse
effector cells (E/T=0, 20 or 60) with or without GV5 was plotted. E/T means effector to target ratio.
doi:10.1371/journal.pone.0029728.g009
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and RH7777 cell lines expressing CD44-GFP proteins were
maintained in FreeStyle293 expression medium with G418
(400 mg/ml). Cells were obtained from American Type Culture
Collection (ATCC), unless otherwise stated. Most cell lines
containing HSC-3 were mentioned elsewhere [45].
Existing therapeutic monoclonal antibodies
Anti-HER1 chimeric Cetuximab (MerckSerono, Rockland,
MA, USA), anti-HER2 humanized Trastuzumab and anti-CD20
chimeric Rituximab (Roche-Chugai, Tokyo, Japan) were used for
the staining of human cells or tissues.
Preparation of a recombinant fully human IgG1 mAb
recognizing CD44R1
MV1, MV2, MV3, MV4 and MV5 fully human IgM mAb were
prepared from cell fusion between spleen cells of Kirin-Medarex
(KM) mice (22) immunized against a recombinant Dex5-v8-v9-
v10-Dex16 (R1a) protein (8) fused to glutathione S-transferase
(GST) and SP2 mouse myeloma cells. The procedure for the cell
fusion and establishment of hybridomas was performed as
described in the next section. In R1a recombinant proteins,
Dex5 or Dex16 respectively corresponds to a partial short peptide
(Dex5, 19 amino acids; Dex16, 8 amino acids) adjacent to v8 or
v10. Reverse-transcribed cDNAs from the variable region of heavy
and light chains, which were cloned from total RNA of hybridoma
cells secreting an IgM (m, k human mAb against CD44R1 (MV5),
were genetically reshaped to cDNAs of human IgG1 (c1, k), and
subcloned to a pBud4.1 expression vector (Invitrogen) having two
separate cloning sites with independent promoters. This expres-
sion vector was transfected into HEK293F cells with a 293fectin
reagent. Two days later, secreted antibodies in the culture medium
were assessed for binding to CD44R1 proteins by FCM. Culture
medium (two liters) containing human IgG against CD44R1 was
concentrated to about 20 ml using a concentration apparatus
(Millipore, Billerica, MA, USA) and precipitated by 50%-saturated
ammonium sulfate. Further purification was performed by affinity
chromatography with protein G-conjugated Sepharose (GE
Healthcare, Uppsala, Sweden). Purity of GV5 human IgG mAb
was determined by SDS-PAGE analysis followed by protein
staining with Coomassie Brilliant Blue (CBB; ICN Biomedicals).
Biotinylation of GV5 was performed using EasyLink Biotin
conjugation kit (Abcam, Tokyo, Japan), in accordance with the
manufacturer’s instructions.
Rat mAb recognizing CD44R1 and CD44s
Female F344/N rats were administered subcutaneous and
intraperitoneal injections (first and second immunizations) fol-
lowed by a final intravenous injection of RH7777 cells expressing
human CD44R1-GFP (1.0 to 5.0610
7) in each immunization at 3-
week intervals. The immune spleen cells (1.0610
8) were fused with
X63 mouse myeloma cells (2.5610
7) using 50% polyethylene
glycol 1540 (Roche, Penzberg, Germany). After the cell fusion,
hybridoma cells were selected in RPMI supplemented with
hypoxanthine, aminopterin and thymidine (506 HAT; Invitro-
gen). From 960 hybridoma cultures, RV7 (c2b, k) anti-human
CD44s, RV9 (c2b, k) anti-human CD44v8 and RV3 (c2a, k) anti-
human CD44v9 rat mAb were selected, and RV7 and RV9 were
used in this study. Purification of mAb was performed with Protein
G-conjugated Sepharose from ascitic fluids precipitated using
Figure 10. ADCC activity of anti-CD44R1 fully human mAb against human tumor cells using human lymphocytes. HSC-3 cells were
labeled with Calcein-AM, and cells (2610
5) were mixed with effector cells of human PBL (5610
5 or 2610
6), which were pre-cultured overnight with IL-
2 with or without mAb in each well of U-bottomed 96-well plate for 7 h. Cytotoxicity was evaluated by the release of Calcein-AM by dead tumor cells
into the medium, and results were automatically recorded using a Terascan VP microfluorocytometer at 1 h intervals for 7 h. Results were analyzed
statistically by two-way ANOVA tests with repeated measures (A) and by two-sided Student’s t tests (A and B). Spots and vertical bars respectively
show means and standard errors.
doi:10.1371/journal.pone.0029728.g010
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determined by SDS-PAGE analysis followed by protein staining
with CBB.
Determination of the epitope region recognized by anti-
CD44 mAb
Reactivity of mAb against various GST-fused recombinant
CD44 proteins, R1a and R1b (Dex5-v8-v9-v10-Dex16), v8, v9,
v10 and ex5 produced in Escherichia coli, was determined by
enzyme-linked immunosorbent assay (ELISA). In Dex5-v8-v9-v10-
Dex16 (R1b) recombinant proteins, Dex5 or Dex16 respectively
corresponds to a partial short peptide (Dex5, 3 amino acids;
Dex16, 2 amino acids) adjacent to v8 or v10. Aliquots (50 ml) of
antigens diluted to 20 mg/ml in phosphate-buffered saline (PBS)
were passively adsorbed in triplicate in wells of polyvinylchloride
96-well plates (Sumitomo Bakelite, Tokyo, Japan) overnight at
4uC. Each well was treated with 100 ml of Block Ace (Dainihon
Seiyaku, Osaka, Japan) for 3 h at 37uC to inhibit nonspecific
binding of the staining reagents. Anti-CD44 human IgM mAb
(hybridoma culture supernatant) was used without dilution, and
GV5 human IgG, RV3, RV7 and RV9 rat IgG were diluted to
10 mg/ml in PBS containing 1% bovine serum albumin (BSA;
ICN Biomedicals). Fifty ml of anti-CD44 mAb or anti-GST goat
polyclonal antibody (GE Healthcare; 1:300 diluted in 1% BSA-
PBS) was added and incubated for 1 h at 37uC. Following
intensive washing with PBS containing 0.05% Tween 20 (T-PBS),
50 ml of 1:1000 diluted species-specific horseradish peroxidase
(HRP)-conjugated donkey anti-human, anti-rat or anti-goat IgG
(H+L) (Jackson ImmunoResearch, West Grove, PA, USA) was
added to each well and incubated for 60 min at room
temperature. After wells were washed intensively with T-PBS,
they were supplemented with 0.1 M citric-acetate buffer (pH 6.0)
containing 3, 39,5 ,5 9-tetramethylbenzidine (0.1 mg/ml) and
0.01% H2O2 (50 ml in each well). Color development in the wells
was stopped after 5 to 10 minutes by the addition of 0.5 M H2SO4
(75 ml in each well), and the optical density of the solution at
450 nm was measured with a Model 550 microplate reader (Bio-
Rad, Hercules, CA).
Flow cytometry (FCM)
For cell-surface staining, cells (3.0610
5)i n5 0 ml of PBS
containing 1% BSA were mixed with primary antibodies (50 ml)
of undiluted hybridoma culture supernatant or purified mAb
diluted to 10 mg/ml in 1% BSA-PBS and incubated for 1 h at 4uC.
After three washes with PBS, cells were incubated at 4uC for
30 min in 50 ml of 1:200 diluted goat anti-human IgG and IgM
(H+L) antibodies labeled with fluorescein isothiocyanate (FITC) or
phycoerythrin (PE) (Jackson ImmunoResearch). After three washes
with PBS, cells were suspended in PBS containing 0.2% BSA, and
analyzed with an Accuri C6 flow cytometer (Tomy Digital
Biology, Tokyo, Japan) or a BD-LSR flow cytometer (Becton-
Dickinson, Sunnyvale, CA, USA). For the quantification of the
expression of cell-surface antigen, subtracted mean fluorescence
intensity (DMFI) was calculated.
Immunohistological analysis (IHA)
Tissue sections (5 mm thick) of ME180 human cancer
xenografts, which developed in athymic mice and were snap-
frozen in OCT embedding medium (Sakura Fineteck, Tokyo,
Japan) using liquid nitrogen, were prepared using a CM1800
cryostat (Leica Microsystems, Wetzlar, Germany). Sections were
fixed in 4% paraformaldehyde (PFA) in PBS or cold acetone,
treated with Block Ace (Dainihon Seiyaku) for 1 h, and incubated
with hybridoma culture supernatant (MV1, MV2, MV3, MV4
or MV5 human mAb) diluted 1:3 with 1% BSA-PBS or
humanized mAb (GV5, Trastuzumab or Rituximab) diluted to
10 mg/ml with 1% BSA-PBS overnight at room temperature.
Human tissue specimens on various cancer tissue arrays (BB6;
Super Bio Chip Laboratories, Seoul, Korea) and gastric and
colon cancers and appendix (these specimens were collected with
informed consent from gastric or colon cancer patients who
underwent surgery at Kumamoto University Hospital and
informed consent was obtained with documents) were treated
with microwaves (500 W) for 10 min in citrate buffer (pH6.0) for
the retrieval of antigens, treated with Block Ace for 1 h and
incubated with RV7, RV9 or biotinylated GV5 mAb (10 mg/ml
diluted in 1% BSA-PBS) overnight at room temperature. After
washing with PBS, endogenous peroxidase activity of tissues was
inhibited by immersing sections in 3% H2O2-methanol for
5 min. After being rinsed in PBS, tissue sections were incubated
with biotinylated goat anti-human IgG and IgM (H+L),
biotinylated goat anti-human IgG Fcc or biotinylated donkey
anti-rat IgG (H+L) (Jackson ImmunoResearch) diluted 1:1000 in
1% BSA-PBS for 1 h. This step was skipped in the case of the
staining with biotinylated GV5. After three washes with PBS,
samples were treated with avidin-biotin-peroxidase complex
(ABC) reagent (Vector Laboratories, Burlingame, CA, USA)
diluted 1:200 in 0.1% BSA-PBS for 45 min. After three more
washes with PBS, tissue sections were incubated with 0.05%
3,39-diaminobenzidine (DAB; Dojin Chemicals, Kumamoto,
Japan) and 0.01% H2O2 in 0.1 M Tris-HCl (pH 7.4), and
counterstained with hematoxylin. Samples were dehydrated with
ethanol (50%, 70%, 75%, 90%, 95% and 99%, successively),
cleared in xylene and mounted in Permount (Fisher Scientific,
Fair Lawn, NJ, USA). The location of antibody-defined
components was observed under an Axiolab microscope (Zeiss,
Hamburg, Germany) and photographed.
Evaluation of therapeutic effect of an anti-CD44R1 mAb
on human tumors in athymic mice
Male athymic mice (KSN strain) at 6 weeks of age (Shimizu
Animal Farm, Kyoto, Japan), housed in a controlled environment
at 22uC in a specific-pathogen-free facility, were randomly
distributed into two groups (with or without treatment of mAb).
Adherent human tumor cells in culture dishes were trypsinized
and washed with PBS three times and re-suspended in PBS. In the
first experiment, ME180 human tumor cells (1.0610
6) with or
without mAb (50 mg/site) in 200 ml of PBS were subcutaneously
inoculated into the right dorsal flank of each animal (tumor
neutralization model [33]). In the second experiment, aliquots of
200 ml of the cell suspensions of HSC-3 human tumor cells
(1.0610
6) were subcutaneously inoculated into the right dorsal
flank of each animal (day 0), and 500 ml of PBS with or without
mAb (100 mg) was intraperitoneally injected at day 7 and day 14
(established tumor model [35]). The size of each tumor formed
was periodically measured, and tumor volume (mm
3) was
calculated by the formula 0.46(length)6(width)
2 [30–32]. All mice
were used with the approval (approval IDs: KAPS-19-039, -042, -
043 and KAPS-22-004) of the Committee for the Care and Use of
Laboratory Animals at Kinki University.
Internalization of CD44 proteins by the treatment with
mAb
HSC-3 cells were cultured for 12 h with or without GV5
(10 mg/ml) at 37uC, and incubated with FITC-conjugated donkey
anti-human IgG (H+L) antibodies (Jackson ImmunoResearch) for
Fully Human Monoclonal Antibody to Human CD44v
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cells was analyzed by FCM with a BD-LSR flow cytometer.
Complement-dependent cytotoxicity (CDC)
Target cells (1.5610
5), sera as complement source (1:10 diluted)
and mAb (10 mg/ml) at the final concentration were incubated in
each well of U-bottomed 96-well plate (Nunc-Thermo Scientific)
for 1 h at 37uC, and 4,69-diamidino-2-phenylindole (DAPI;
Sigma-Aldrich) was added to each well (0.5 mg/ml). Percentages
of DAPI-stained cells (dead cells) were calculated by FCM with a
BD-LSR flow cytometer.
Antibody-dependent cellular cytotoxicity (ADCC)
For mouse effector cells, ADCC was assessed as follows. HSC-3
cells (2610
5) were mixed with splenocytes (4610
6 or 1.2610
7)o f
KNS nude mice, which were pre-cultured for 12 h with
recombinant human interleukin 2 (IL-2, 100 IU; Shionogi & Co.
Ltd., Osaka, Japan) in 650 ml of RPMI with or without mAb
(10 mg/ml) in each well of 12-well plate (Sumitomo Bakelite;
Suspension Culture Treated) for 5 h at 37uC, and propidium
iodide (PI; Sigma-Aldrich) was added to each well (0.5 mg/ml).
Percentages of PI-stained cells (dead cells) were calculated by FCM
with an Accuri C6 flow cytometer. For human effector cells,
ADCC was assessed using a Terascan VP microfluorocytometer
(Minerva Tech Co., Tokyo, Japan). HSC-3 (2610
4 cells) in
DMEM with 7% FBS (200 ml) were cultured on wells of a 96-well
flat-bottomed microplate (Costar 3596; Corning Inc., Corning,
NY) for 24 h. The monolayer HSC-3 cells were stained using
Calcein-AM (Dojin Chemicals) at a concentration of 10 mg/ml at
37uC for 1 h. Following gentle washing of cells attached to the
bottom of wells, human PBL, which were pre-cultured with IL-2
(100 IU) for 12 h, were added (5610
4 or 2610
5 cells/well) with or
without GV5 at a final concentration of 1 mg/ml. After the
distribution of the materials into wells, the plate was centrifuged at
1006g for 2 min to cause the effector cells to settle. DMEM with
7% FBS was added to empty wells (200 ml/well) for measurement
of a background fluorescence level. All sets of measurements were
carried out in triplicate wells. Fluorescence intensity of each well
was measured by focusing an inverted epifluorescent microscope
equipped with Terascan VP on a cell surface and adjusting the
sensitivity of a photomultiplier. Thereafter, 10 ml of Decon 90
(Decon Laboratories, Hove, UK) was added to a well for the
maximal release measurement for entirely injured cells. The plate
was incubated for the indicated periods up to 7 h at 37uC. The
extent of Calcein-AM release in the experimental wells was
automatically calculated and is expressed as the percentage of
cytotoxicity.
Statistical analyses
We analyzed results statistically by two-sided Student’s t tests
with Microsoft Excel 2007 (Microsoft, Redmond, WA), and/or by
two-way analysis of variance (ANOVA) tests with repeated
measures using R statistical package (www.r-project.org).
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